Population Pharmacokinetics of Moxifloxacin in Children

[1]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous colistin in pediatric patients: Implications for selection of dosage regimens. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Eissing,et al.  Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin , 2019, CPT: pharmacometrics & systems pharmacology.

[3]  H. Stass,et al.  Pharmacokinetics, Safety, and Tolerability of Single‐Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study , 2019, Journal of clinical pharmacology.

[4]  Kashyap Patel,et al.  A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models , 2018, CPT: pharmacometrics & systems pharmacology.

[5]  C. Staatz,et al.  Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients , 2018, Journal of paediatrics and child health.

[6]  Hesham S. Al-Sallami,et al.  Prediction of Fat-Free Mass in Children , 2015, Clinical Pharmacokinetics.

[7]  L. Wiesner,et al.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Jensen-Fangel,et al.  Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in Empiric Treatment of Community-Acquired Pneumonia , 2015, Antimicrobial Agents and Chemotherapy.

[9]  L. Piddock,et al.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. , 2014, Trends in microbiology.

[10]  I. Raffaldi,et al.  Moxifloxacin for the treatment of pulmonary tuberculosis in children: A single center experience , 2014, Pediatric Pulmonology.

[11]  J. Barrett,et al.  Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization , 2013, Clinical Cancer Research.

[12]  N. Holford,et al.  Understanding dosing: children are small adults, neonates are immature children , 2013, Archives of Disease in Childhood.

[13]  C. Kloft,et al.  Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. , 2013, The Journal of antimicrobial chemotherapy.

[14]  K. Shen,et al.  Combination therapy with immune‐modulators and moxifloxacin on fulminant macrolide‐resistant Mycoplasma pneumoniae infection: A case report , 2013, Pediatric pulmonology.

[15]  Susan L. Furth,et al.  Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C , 2012, Kidney international.

[16]  M. Laughon,et al.  Pharmacokinetics of Moxifloxacin in an Infant With Mycoplasma hominis Meningitis , 2012, The Pediatric infectious disease journal.

[17]  U. Holzgrabe,et al.  Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation , 2009, Antimicrobial Agents and Chemotherapy.

[18]  R. Owens,et al.  Clinical pharmacodynamics of quinolones. , 2003, Infectious disease clinics of North America.

[19]  A. MacGowan,et al.  Development of the quinolones. , 2003, The Journal of antimicrobial chemotherapy.

[20]  D. Hoban,et al.  A Critical Review of the Fluoroquinolones , 2002, Drugs.

[21]  C. Kohlsdorfer,et al.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. , 1999, The Journal of antimicrobial chemotherapy.

[22]  H. Stass,et al.  Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects , 1998, Antimicrobial Agents and Chemotherapy.

[23]  W. Carlton,et al.  Histologic and Histochemical Changes in Articular Cartilages of Immature Beagle Dogs Dosed with Difloxacin, a Fluoroquinolone , 1990, Veterinary pathology.

[24]  J. Frazier,et al.  Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics , 2016, Clinical Pharmacokinetics.

[25]  Alan Forrest,et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  I. Chahoud,et al.  Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations , 2005, Archives of Toxicology.

[27]  D. Hoban,et al.  A critical review of the fluoroquinolones: focus on respiratory infections. , 2002, Drugs.